

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/06298

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.    |
|------------|---|--------------------------|
| P,X        | QUINTIERI, L. ET AL: "Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: Effect in mice bearing hepatic metastases" BRITISH JOURNAL OF CANCER, vol. 79, no. 7-8, March 1999 (1999-03), pages 1067-1073, XP000893191 the whole document | 1,4,5,8, 13,15, 16,18,19 |
| X          | VASEY, P.A. ET AL: "Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762)" CANCER RESEARCH, vol. 55, no. 10, 1995, pages 2090-2096, XP000891501 the whole document especially page 2091, Table 1             | 1-3,5, 10-12, 18,19      |

-/--

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 April 2000

Date of mailing of the international search report

03/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Mair, J

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/06298

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | TAUB, R.N. ET AL: "Phase II study of methoxymorpholinodoxorubicin in advanced sarcomas (PNU/S2243 (FCE 23762))" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 16, 1997, page A1831 XP002135896 abstract   | 1,4-6,<br>18,19       |
| X          | BAKKER, M. ET AL: "Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients" BRITISH JOURNAL OF CANCER, vol. 77, no. 1, January 1998 (1998-01), pages 139-146, XP000893190 the whole document especially page 140, Table 1 | 1,4-6,<br>18,19       |
| Y          | ROBERT, J. ET AL: "Pharmacokinetics and metabolism of anthracyclines" CANCER SURVEYS, vol. 17, 1993, pages 219-252, XP000893095 page 228, line 4 -page 229, line 38 page 239, line 25 -page 242, line 23 especially page 242, line 15-17   | 1-5,8,9,<br>13-19     |
| Y          | ROUGIER, P. ET AL: "Intérêt des chimiothérapies loco-régionales par les anthracyclines" PATHOLOGIE BIOLOGIE, vol. 35, no. 1, 1987, pages 123-128, XP000893118 the whole document especially page 128, righthand column   | 1-5,8,9,<br>13-19     |
| Y          | KIRK, S. ET AL: "Irresectable hepatoma treated by intrahepatic iodized oil doxorubicin hydrochloride: Initial results" SURGERY, vol. 109, no. 6, 1991, pages 694-697, XP000893192 the whole document   | 1-5,8,9,<br>13-19     |
| Y          | CARR, B.I. ET AL: "Prolonged survival with chemotherapy alone for hepatocellular carcinoma (HCC) with intra-arterial chemotherapy" PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 13, March 1994 (1994-03), page 205 XP000893111 abstract  | 1-5,8,9,<br>13-19     |
|            | ---  |                       |
|            | ---/---  |                       |

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/06298

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.        |
|------------|---|------------------------------|
| Y          | <p>CARR, B.I. ET AL: "Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: Interim analysis" SEMINARS IN ONCOLOGY, vol. 24, no. 2 suppl. 6, April 1997 (1997-04), pages S6-97-S6-99, XP000893102<br/>the whole document -----</p> | 1-5,8,<br>13,15,<br>16,18,19 |